Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Astellas Pharma Inc.
  6. News
  7. Summary
    4503   JP3942400007


SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Astellas Pharma : World Anti-Doping Agency and Astellas Announce Global Initiative to Prevent Misuse and Abuse of Medicines for Doping in Sports

10/13/2016 | 10:04pm EDT

MONTREAL and TOKYO, 14 October 2016 - The World Anti-Doping Agency (President: Sir Craig Reedie, 'WADA') and Astellas Pharma Inc. (TSE: 4503: President and CEO: Yoshihiko Hatanaka, 'Astellas') today announced a global agreement to partner on the prevention of misuse and abuse of medicines for doping in sports. Doping in sports relies primarily on the misuse and abuse of commercially available medicines, as well as compounds in development that are not as well-known or easily detected.

To support WADA in its efforts to address this issue, Astellas will identify compounds solely developed by Astellas or its affiliates with the potential for sport-related doping abuse and will cooperate in sharing relevant information to aid WADA in the organization's development of detection methods for these compounds. Additionally, Astellas will cooperate with WADA to minimize the risk of misuse of compounds with doping potential during clinical trials to avoid opportunities for abuse.

'WADA is encouraged to be partnering with Astellas on the prevention of misuse and abuse of medicines for doping in sports,' said Sir Craig Reedie, President, WADA. 'It's a win-win arrangement. Essentially, Astellas will inform WADA during compound development if there is potential for future abuse in sport; and, the Agency commits to inform Astellas should it uncover evidence of black market supply involving their compounds. This partnership acknowledges that the impacts of doping extend well beyond elite athletes to include society on the whole.'

'Astellas is committed to ensuring the safe and effective use of its therapies in appropriate settings, and we are proud to be the first Japan-based company to partner with WADA in its efforts to prevent the inappropriate use of medical products through doping,' said Kenji Yasukawa, Ph.D., Chief Strategy Officer, Astellas. 'Enhancing performance in sports through doping is considered a serious public health issue by the sport movement and public authorities worldwide. It is critical that pharmaceutical companies play a role in helping to address this important public health concern.'

Astellas' activities are aligned with recent guidance published by WADA and the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) to help pharmaceutical and biotechnology companies increase their role in the fight against sport-related doping. The guidance, titled Points to Consider: Identification of Compounds with Potential for Doping Abuse and Sharing of Information with WADA, includes best practices on establishing a voluntary process for determining the potential doping risk of compounds in their development pipelines before they are commercially available.

The Points to Consider guidance is an extension of the Joint Declaration on Cooperation in the Fight Against Doping that was signed by IFPMA and WADA in July 2010, and endorsed by the global Biotechnology Industry Organization (BIO) in June 2011, to combat the latest doping techniques.

To learn more about Astellas' commitment to its anti-doping efforts, please read the company's newly published Position Statement, available at https://www.astellas.com/en/corporate/comp_policy/anti_doping.html.

Astellas Pharma Inc. published this content on 14 October 2016 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 14 October 2016 02:04:03 UTC.

© Publicnow 2016
09/09ASTELLAS PHARMA : Updates “Contact for Potential Acquisition of ' R&D Prog..
09/02ASTELLAS PHARMA : Nitto, and M. Heart Partnering for ECG testing service
09/01Astellas Provides Update on ASPIRO Clinical Trial of AT132 in Patients with X..
08/31ASTELLAS PHARMA : Announces Personnel Changes
08/30ASTELLAS PHARMA : Launches its Corporate Website's New Modalities~Approac..
08/20SECTOR UPDATE : Health Care Stocks Mixed Premarket Friday
08/20FIBROGEN : Receives $120 Million Milestone Payment With Approval of Evrenzo in E..
08/20ASTELLAS PHARMA : Receives European Commission Approval for First-in-Class EVREN..
08/19ASTELLAS PHARMA : Receives European Commission Approval for First-in-Class EVREN..
08/19ASTELLAS PHARMA : Receives EC Approval for First-inClass EVRENZO (roxadustat) fo..
More news
Sales 2022 1 325 B 12 044 M 12 044 M
Net income 2022 196 B 1 779 M 1 779 M
Net cash 2022 478 B 4 341 M 4 341 M
P/E ratio 2022 17,7x
Yield 2022 2,65%
Capitalization 3 500 B 31 855 M 31 819 M
EV / Sales 2022 2,28x
EV / Sales 2023 1,92x
Nbr of Employees 15 455
Free-Float 98,9%
Duration : Period :
Astellas Pharma Inc. Technical Analysis Chart | 4503 | JP3942400007 | MarketScreener
Technical analysis trends ASTELLAS PHARMA INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 13
Last Close Price 1 889,00 JPY
Average target price 2 451,54 JPY
Spread / Average Target 29,8%
EPS Revisions
Managers and Directors
Kenji Yasukawa President, CEO & Representative Director
Naoki Okamura Representative Director, VP & Head-Finance
Yoshihiko Hatanaka Chairman
Yoshitsugu Shitaka Chief Scientific Officer
Fumiaki Sakurai Head-Business Administration & Compliance
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON4.68%434 939
ROCHE HOLDING AG11.70%327 062
PFIZER, INC.20.81%249 329
NOVO NORDISK A/S51.34%233 887